Viva Biotech Holdings disclosed that on 13 May 2026 it repurchased 1.60 million ordinary shares on the Hong Kong Stock Exchange, paying between HKD 1.50 and HKD 1.52 per share. The transaction cost HKD 2.41 million and all repurchased shares are earmarked for cancellation.

Including earlier buybacks on 8, 11 and 12 May, Viva Biotech has acquired 8.48 million shares in the current series at a volume-weighted average price of approximately HKD 1.55 per share. The combined repurchases represent 0.40 % of the company’s issued share capital authorised under the June 2025 mandate, which permits the repurchase of up to 212.84 million shares.

Following the latest transactions, the company’s issued share count remains at 2.13 billion shares, as the repurchased shares have not yet been cancelled. A moratorium on new share issues or transfers of treasury shares is in place until 12 June 2026, in line with Hong Kong listing regulations governing share buybacks.

The board confirms that all repurchases were executed within the scope of the mandate approved on 12 June 2025 and in compliance with applicable listing rules.